Ignite Creation Date:
2025-12-25 @ 2:29 AM
Ignite Modification Date:
2025-12-27 @ 10:51 AM
Study NCT ID:
NCT03888534
Status:
WITHDRAWN
Last Update Posted:
2020-09-28
First Post:
2019-03-22
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)
Sponsor:
Millennium Pharmaceuticals, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-10-31
Start Date Type:
ESTIMATED
Primary Completion Date:
2022-08-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2022-08-30
Completion Date Type:
ESTIMATED
First Submit Date:
2019-03-22
First Submit QC Date:
None
Study First Post Date:
2019-03-25
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-09-24
Last Update Post Date:
2020-09-28
Last Update Post Date Type:
ACTUAL